Regen BioPharma, Inc.
RGBP
$0.00
$0.000.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -21.95% | 23.49% | -66.28% | -90.75% | -34.64% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 350.41% | 455.20% | 332.21% | 279.31% | -274.10% |
| Total Other Non-Cash Items | -9.33% | -73.39% | 87.22% | 301.60% | 168.21% |
| Change in Net Operating Assets | 159.23% | 168.66% | 100.05% | 113.76% | 0.00% |
| Cash from Operations | -3.32% | 12.86% | 21.43% | 48.96% | 24.08% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -49.50% | -28.68% | 94.35% | 344.26% | 110.15% |
| Total Debt Repaid | -245.19% | -181.14% | -261.10% | -- | 180.20% |
| Issuance of Common Stock | 963.83% | 83.49% | -28.86% | -89.68% | -94.73% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 19.63% | 0.96% | -2.16% | -28.31% | -41.01% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 97.50% | 98.04% | 103.54% | 157.19% | -198.36% |